Daniel Nicolae MURARIU, Sinziana BARBU, Loredana CIRLAN, Larisa ZIDARU, Daniel CORIU, Sorina Nicoleta BADELITA
Abstract
Purpose: We report a single center study experience with subcutaneous Immunoglobulin administrations in patients with secondary hematological defficiencies, aiming to explore the outcomes of the infectous complications in these patients.
Materials and methods: Evaluation of a lot of patients from the Hematology Department of Fundeni Clinical Institute that have been treated with subcutaneous Immunoglobulins since may 2022 untill september 2024; a retrospective, unicentric study, based on data from electronic records.
Results: We evaluated 32 patients for a period of over 2 years, diagnosed with multiple myeloma receiving specific therapy, that presented multiple infectious complications wtih at least 2 subcutaneous immunoglobulin (SCIg) administrations. The median age of the patients was 67 years old and 16 patients (50%) of the patients patients had hypogammaglobulinemia. We analzyed the number and severity of infections before and after multiple SCIg administrations – prior to SCIg administration 21 patients(65.63%) patients had severe grade 3 or 4 infections, with half of the patients (16) having hypogammaglobulinemia. Following multiple SCIg administrations, 24 patients (75%) did not present any infection following 3 consecutive administrations, and 12 out of 16 patients with hypogammaglobulinemia (75%) having IgG values elevated over 5 g/l.
Conclusions: The obtained results demonstrated a great reduction of the frequency and severity of infections in patients with SCIg administrations. Early administrations may decrease the risk of infection complications and mortality
https://doi.org/10.59854/dhrrh.2024.2.3.117